Book · 2012
cypate-d: -(+)-glucosamine (cyp-GlcN), and d: -(+)-glucosamine-cypate-d: -(+)-glucosamine (cyp-2GlcN)
Arvind Chopra
National Center for Biotechnology Information (US) eBooks
Abstract
Increased nutritional requirements are a characteristic feature of neoplastic tumor cells, and because these lesions do not rely on mitochondrial oxidation for energy, most of the energy in these cells is generated through glycolysis (1). To keep up with the high nutritional and energy needs of a malignant tumor, the transformed cells in the lesion show a 20- to 30-fold higher rate of glucose uptake and glycolysis compared with normal cells. As a consequence, to meet the increased demand for glucose, the facultative glucose transport proteins (GLUTs; there are 14 known isoforms of these proteins, designated GLUT1 through GLUT14) that facilitate glucose uptake are upregulated on the plasma membranes of the tumor cells (2). In general, GLUT1 and GLUT3 are able to transport glucosamine (GlcN) in addition to glucose and are overexpressed in the different cancer types, including prostate cancer. In addition, an elevated expression of these transporters correlates with the malignant potential of the lesions and indicates a poor prognosis for the patient (2). Among the different glucose transporters, GLUT2 and GLUT4 can also transport GlcN, and both of these isoforms are transcriptionally repressed by the p53 protein, a tumor suppressor protein that regulates the cell cycle and promotes apoptosis (3). GLUT1 and GLUT4 exhibit a similar affinity for glucose and GlcN, but GLUT2 has an approximate 20-fold higher affinity for GlcN than for glucose (3). The d -(+)-glucosamine-cypate- d -(+)-glucosamine; cyp-2GlcN) to visualize luciferase-expressing PC3 cell (PC3-luc) xexograft tumors in mice (3). The biodistribution of cyp-GlcN and cyp-2GlcN was also studied in these animals.